Abstract:Background: Tolerogenic dendritic cells (DCs) offer promising prospects as cell-based treatment for autoimmune diseases, including systemic lupus erythematosus (SLE). However, the precise mechanisms accounting for tolerogenic DCs mediated immunoregulation in SLE remain incompletely understood. Objectives: We previously identified tolerogenic CD1c+DCs played important roles in mesenchymal stem cells transplantation treatment for SLE. Here we further investigate the immunoregulatory effect of CD141+DCs in the pathogenesis of lupus. Methods: A total of 12 SLE patients and 12 age-matched and gender-matched healthy subjects were included in the study. The number and percentage of peripheral blood CD141+DCs and their expression of functional costimulatory markers (CD40, CD80, CD83, and CD86) were compared between SLE patients and healthy controls. Moreover, the tolerogenic property of CD141+DCs and CD1c+DCs were compared by stimulating with LPS or SLE serum. Results: Our research revealed the number of peripheral CD141+DCs decreased in lupus, which was negatively correlated with SLE disease activity index score. Moreover, CD141+DCs in SLE patients exhibited distinct tolerogenic properties by decreasing expression of CD40, CD80, CD86 compared with healthy controls. Furthermore, CD141+DCs exhibited superior tolerogenicity compared to CD1c+DCs in SLE, by reducing expression of CD86 and reducing production of TNFα. Conclusion: CD141+DCs may play a more significant role than the commonly studied CD1c+DCs in ameliorating immune dysfunction and maintaining immune homeostasis in SLE. Our findings contribute to a better understanding of the immunoregulatory mechanisms underlying SLE and pave the way for novel therapeutic approaches targeting CD141+DCs. REFERENCES: [1] Yuan X, Qin X, Wang D, et al. Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients. Nat Commun. 2019;10(1):2498. [2] Chu CC, Ali N, Karagiannis P, et al. Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J Exp Med. 2012;209(5):935-945. [3] Comi M, Avancini D, Santoni de Sio F, et al. Coexpression of CD163 and CD141 identifies human circulating IL-10-producing dendritic cells (DC-10). Cell Mol Immunol. 2020;17(1):95-107. [4] Sachamitr P, Leishman AJ, Davies TJ, Fairchild PJ. Directed Differentiation of Human Induced Pluripotent Stem Cells into Dendritic Cells Displaying Tolerogenic Properties and Resembling the CD141+ Subset. Front Immunol. 2018;8:1935. [5] Worbs T, Hammerschmidt SI, Förster R. Dendritic cell migration in health and disease. Nat Rev Immunol. 2017;17(1):30-48. [6] Adamik J, Munson PV, Hartmann FJ, et al. Distinct metabolic states guide maturation of inflammatory and tolerogenic dendritic cells. Nat Commun. 2022;13(1):5184. [7] Breton G, Lee J, Zhou YJ, et al. Circulating precursors of human CD1c+ and CD141+ dendritic cells. J Exp Med. 2015;212(3):401-413. Acknowledgements: NIL. Disclosure of Interests: None declared.

Distinct Roles of Myeloid and Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Dendritic Cells in Systemic Lupus Erythematosus: from Pathogenic Players to Therapeutic Tools.

Predominant Role of Plasmacytoid Dendritic Cells in Stimulating Systemic Autoimmunity.

Aberrant CD200/CD200R1 Expression and Function in Systemic Lupus Erythematosus Contributes to Abnormal T-cell Responsiveness and Dendritic Cell Activity

Pivotal Functions of Plasmacytoid Dendritic Cells in Systemic Autoimmune Pathogenesis.

Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus

The role of dead cell clearance in the etiology and pathogenesis of systemic lupus erythematosus: dendritic cells as potential targets

Abnormalities in Circulating Plasmacytoid Dendritic Cells in Patients with Systemic Lupus Erythematosus.

Molecular Mechanisms Behind the Role of Plasmacytoid Dendritic Cells in Systemic Sclerosis

AB1118 HUMAN CD141+ DENDRITIC CELLS (dcs) REPRESENT A UNIQUE TOLEROGENIC DC SUBSET THAT INDUCE IMMUNE-TOLERANCE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

Hyperactivated MyD88 signaling in dendritic cells, through specific deletion of Lyn kinase, causes severe autoimmunity and inflammation

Induction of Dendritic Cell Differentiation by IFN-α in Systemic Lupus Erythematosus

Role of dendritic cells in psoriasis formation

Study of the expression of interleukin-12 and interferon-α and their relationships with the dendritic cell subsets in systemic lupus erythematosus patients

MDSC-derived S100A8/9 contributes to lupus pathogenesis by promoting TLR7-mediated activation of macrophages and dendritic cells

Systemic lupus erythematosus patients have increased number of circulating plasmacytoid dendritic cells, but decreased myeloid dendritic cells with deficient CD83 expression.

Dendritic Cells Induced and Correlation with SLE Activity Criteria in Systemic Lupus Erythematosus Patients

Expanding Roles of Noncoding RNAs in the Pathogenesis of Systemic Lupus Erythematosus

Systemic Autoimmune Disease Induced by Dendritic Cells That Have Captured Necrotic but Not Apoptotic Cells in Susceptible Mouse Strains

Single-cell Analyses Reveal Functional Classification of Dendritic Cells and Their Potential Roles in Inflammatory Disease.